PATIENTS
Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment
ACOBIOM
Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy
CLINICS & HOSPITALS
Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences
GemciTest ®
The first diagnostic to predict the patient response in pancreatic cancer treatment
PANCREATIC CANCER
A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.
DIAGNOSTIC
A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response
GEMCITABINE
The less toxic and expensive chemotherapy in pancreatic cancer treatment
BLOOD RNA-SIGNATURE
A combination of biomarkers to identify patients most likely to benefit from gemcitabine
Prescribing the right treatment to the right patient requires funds.
To obtain more information about ACOBIOM’s developments, please visit the “Investors” page
Our Expertises
Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.
BIOMARKERS
Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.
BIOINFORMATICS
Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic and Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.
PRECISION MEDICINE
Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.
GENOMICS
A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.
Latest News
Target genes and specific reference genes, a unique marriage for successful RT-PCR experiments
Gene expression analyses by real-time PCR (or qPCR) are currently used to measure drug effects or to identify subpopulations of patients mostly likely to benefit from a specific therapy. The success of a qPCR experiment relies on the combination of a unique triptych: the selection of relevant and regulated target genes, the identification of a couple or more stable and experiment-specific reference genes, also called housekeeping genes, and robust statistical analyses. Thus, if some consider the target genes as the Kings of their experiment, the reference genes are the Queens of the equation!
Read more
RNA/DNA analyses to identify or confirm biomarkers and clinical endpoints
ACOBIOM is involved in a national collaborative clinical research program: OncoSNIPE®, whose objectives are to identify early and late markers of resistance to 1st line treatments in locally advanced or metastatic triple negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. In this project, the scientific team of the company develops an optimized pipeline of bioinformatics and biostatistics tools to perform in routine, in blood and tissue, DNA and RNA analyses from hundreds of sequencing experiments.
These types of approaches associated with standardized protocols are applied to clinical trials with the objective of the identification of prognostic biomarkers associated with new therapies.
ACOBIOM selects and analyzes a panel of RNA biomarkers related to inflammation for the clinical evaluation of an innovative medical device
On behalf of a European consortium, ACOBIOM performed omics data analysis to strengthen the biological and clinical evaluation of an innovative medical device that aims to reduce chronic gum inflammation and restore oral soft tissue health. These analyses of tissue inflammasome are a recognition of the company’s technology platform, its technical expertise in the identification and selection of a panel of relevant RNA biomarkers related to inflammation, as well as in the biological and statistical analysis of transcriptomic data.
Read moreABOUT ACOBIOM
Since its foundation, Acobiom has always been at the forefront of Medical Innovation.
Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.
FOR MORE INFORMATION
